Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Practice

High-dose influenza vaccination

Daniel Dalcin and Jeffrey C. Kwong
CMAJ March 18, 2019 191 (11) E313; DOI: https://doi.org/10.1503/cmaj.181477
Daniel Dalcin
Faculty of Medicine (Dalcin), Dalhousie University, Halifax, NS; ICES (Kwong); Public Health Ontario (Kwong); Department of Family and Community Medicine (Kwong), University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey C. Kwong
Faculty of Medicine (Dalcin), Dalhousie University, Halifax, NS; ICES (Kwong); Public Health Ontario (Kwong); Department of Family and Community Medicine (Kwong), University of Toronto, Toronto, Ont.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF
Loading

High-dose influenza vaccine contains 4 times the amount of antigen of standard-dose vaccines

High-dose trivalent inactivated influenza vaccine (HD-TIV) contains 60 μg of hemagglutinin per strain, whereas standard-dose vaccines (SD-TIV) contain 15 μg. Given the burden of influenza A subtype H3N2 in older adults and evidence of better efficacy of HD-TIV relative to SD-TIV (Box 1),1–4 Canada’s National Advisory Committee on Immunization recommends HD-TIV over SD-TIV for adults aged 65 years and older; however, the comparative effectiveness of HD-TIV over other options (MF59-adjuvanted TIV or standard-dose quadrivalent influenza vaccine) is uncertain.5 The HD-TIV is publicly funded for adults aged 65 and older in Ontario and for long-term care residents aged 65 and older in Saskatchewan, Manitoba and Prince Edward Island.

Box 1: Absolute outcome comparisons among adults aged 65 years and older receiving SD-TIV and HD-TIV
OutcomeSD-TIVHD-TIV
Laboratory-confirmed influenza11.9%1.4%
Hospital admissions for laboratory-confirmed influenza21.10 per 10 000 person-weeks0.86 per 10 000 person-weeks
Post-influenza death30.038 per 10 000 person-weeks0.028 per 10 000 person-weeks
Mild adverse events*429.4%34.3%
  • Note: HD-TIV = high-dose trivalent inactivated influenza vaccine,

  • SD-TIV = standard-dose trivalent inactivated influenza vaccine.

  • ↵* For example, fever, headache, malaise and myalgia.

In older adults, HD-TIV is more efficacious than SD-TIV

A clinical trial involving 31 989 adults 65 years of age and older found that HD-TIV was 24% (95% confidence interval [CI] 10% to 37%) more efficacious than SD-TIV in preventing laboratory-confirmed influenza, with 23% higher efficacy (95% CI 6% to 38%) against influenza A subtype H3N2.1 Influenza A subtype H3N2 accounts for most severe illnesses among older adults. To prevent 1 additional case of influenza, 200 individuals need to receive HD-TIV instead of SD-TIV.1

HD-TIV is associated with reduced hospital admissions and emergency department visits in older adults

A cohort study including adults 65 years and older found that those who had received HD-TIV (n = 929 730) had a 22% (95% CI 16% to 27%) reduction in influenza-coded hospital admissions and emergency department visits compared with those who received SD-TIV (n = 1 615 545).2

HD-TIV is associated with reduced post-influenza deaths among older adults

A cohort study including 2 722 909 adults aged 65 years and older found that HD-TIV was associated with a 36% (95% CI 9% to 56%) reduction in post-influenza deaths compared with SD-TIV during the 2012/13 season, but no reduction during the 2013/14 season.3

Mild adverse events occur more often with HD-TIV than with SD-TIV

Short-term data from clinical trials showed higher rates of mild systemic reactions (e.g., fever) among individuals receiving HD-TIV than among those receiving SD-TIV (relative risk 1.2, 95% CI 1.1 to 1.3), but not serious adverse events (relative risk 0.92; 95% CI 0.85 to 0.99).1,4

Footnotes

  • CMAJ Podcasts: author interview at https://soundcloud.com/cmajpodcasts/181477-five

  • Competing interests: None declared.

  • This article has been peer reviewed.

References

  1. ↵
    1. DiazGranados CA,
    2. Dunning AJ,
    3. Kimmel M,
    4. et al
    . Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014;371:635–45.
    OpenUrlCrossRefPubMed
  2. ↵
    1. Izurieta HS,
    2. Thadani N,
    3. Shay DK,
    4. et al
    . Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis [published correction appears in Lancet Infect Dis 2015;15: 263]. Lancet Infect Dis 2015;15:293–300.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Shay DK,
    2. Chillarige Y,
    3. Kelman J,
    4. et al
    . Comparative effectiveness of high-dose versus standard-dose influenza vaccines among US Medicare beneficiaries in preventing post-influenza deaths during 2012–2013 and 2013–2014. J Infect Dis 2017;215:510–7.
    OpenUrlCrossRef
  4. ↵
    1. Falsey AR,
    2. Treanor JJ,
    3. Tornieporth N,
    4. et al
    . Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172–80.
    OpenUrlCrossRefPubMed
  5. ↵
    Canadian immunization guide chapter on influenza and statement on seasonal influenza vaccine for 2018–2019. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI). Ottawa: Public Health Agency of Canada; 2018. Available: www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-statement-seasonal-influenza-vaccine-2018-2019.html#2.6 (accessed 2019 Mar. 1).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 191 (11)
CMAJ
Vol. 191, Issue 11
18 Mar 2019
  • Table of Contents
  • Index by author

Podcast

Subscribe to podcast
Download MP3

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
High-dose influenza vaccination
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
High-dose influenza vaccination
Daniel Dalcin, Jeffrey C. Kwong
CMAJ Mar 2019, 191 (11) E313; DOI: 10.1503/cmaj.181477

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
High-dose influenza vaccination
Daniel Dalcin, Jeffrey C. Kwong
CMAJ Mar 2019, 191 (11) E313; DOI: 10.1503/cmaj.181477
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • High-dose influenza vaccine contains 4 times the amount of antigen of standard-dose vaccines
    • In older adults, HD-TIV is more efficacious than SD-TIV
    • HD-TIV is associated with reduced hospital admissions and emergency department visits in older adults
    • HD-TIV is associated with reduced post-influenza deaths among older adults
    • Mild adverse events occur more often with HD-TIV than with SD-TIV
    • Footnotes
    • References
  • Figures & Tables
  • Related Content
  • Responses
  • Metrics
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Pneumopericardium as a complication of pericardiocentesis
  • A blistering variant of phlegmasia cerulea dolens from underlying squamous cell lung cancer
  • Parechovirus infections in infants
Show more Practice

Similar Articles

Collections

  • Article Types
    • Five Things to Know About
  • Topics
    • Infectious diseases
    • Public health
    • Vaccination

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire